[1] Grun F,Blumberg B.Endocrine disrupters as obesogens[J].Mol Cell Endocrinol,2009,304(1/2):19-29. [2] Vandenberg LN,Hauser R,Marcus M,et al.Human exposure to bisphenol A(BPA) [J].Reprod Toxicol,2007,24(2):139-177. [3] Calafat AM,Kuklenyik Z,Reidy JA,et al.Urinary concentrations of bisphenol A and 4-nonylphenol in a human reference population[J].Environ Health Perspect,2005,113(4):391-395. [4] 国先芬,王贻鑫,耿存珍,等.环境激素双酚A的毒理学研究进展[J].环境科学与技术,2013,36(2):86-92. [5] Doerge DR, Twaddle NC, Vanlandingham M,et al.Pharmacokinetics of Bisphenol A in neonatal and adult CD-1 mice: Inter-species comparisons with Sprague-Dawley rats and rhesus monkeys[J]. Toxicology Letters,2011,207(3):298-305. [6] Mielke H, Gundert-Remy U. Bisphenol A levels in blood depend on age and exposure[J]. Toxicol Lett,2009, 190(1):32-40. [7] 张超,邓姗姗,徐蓉,等.胰岛素注射方式对2型糖尿病KK小鼠血脂的影响[J].中国临床药理学与治疗学,2011,16(2):129-134. [8] Patisaul HB,Bateman HL.Neonatal exposure to endocrine active compounds or an ERbeta agonist increases adult anxiety and aggression in gonadally intact male rats[J].Horm Behav,2008,53(4):580-588. [9] Ben Djoudi Ouadda A, Levy E,Ziv E,et al.Increased hepatic lipogenesis in insulin resistance and Type 2 diabetes is associated with AMPK signalling pathway up-regulation in Psammomys obesus[J]. Biosci Rep,2009,29(5):283-292. [10] Byrne CD, Olufadi R, Bruce KD, et al. Metabolic disturbances in non-alcoholic fatty liver disease[J]. Clin Sci (Lond),2009, 116(7): 539-564. [11] Diraison F, Beylot M. Role of human liver lipogenesis and reesterification in triglycerides secretion and in FFA reesterification[J].Am J Physiol,1998,274(2 Pt 1): E321- E327. [12] Postic C, Girard J. Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice[J].J Clin Invest,2008, 118(3): 829-838. [13] Lewis GF, Carpentier A, Adeli K, et al. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes[J].Endocr Rev,2002, 23(2): 201-229. |